Compare MRTN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | ABCL |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1994 | 2020 |
| Metric | MRTN | ABCL |
|---|---|---|
| Price | $14.18 | $3.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 698.9K | ★ 2.4M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,131,455,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.12 | $25.44 |
| P/E Ratio | $65.05 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $9.35 | $1.94 |
| 52 Week High | $14.19 | $6.52 |
| Indicator | MRTN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 68.77 | 49.10 |
| Support Level | $11.43 | $3.37 |
| Resistance Level | N/A | $3.84 |
| Average True Range (ATR) | 0.40 | 0.16 |
| MACD | 0.18 | -0.00 |
| Stochastic Oscillator | 93.30 | 43.33 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.